Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate
in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by
Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient
refusal or withdrawal of patient consent, or unacceptable toxicity